Abstract PS2-09-26: Circulating microRNA and cytokine signatures associated with interstitial lung disease in patients treated with trastuzumab deruxtecanM. Alva Bianchi, E. Ciruelos Gil, I. Diaz et al.|Clinical Cancer Research|2026Cited by 0
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Isabel García-Fructuoso et al.|Breast Cancer Research and Treatment|2026Cited by 0